-
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert PanelD Capodanno, MC Morice, DJ Angiolillo et al. -
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS RegistryJoyce LC, Baber U, Mehran R et al.
-
'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trialAS Gamal, H Hara, PW Serruys et al.
-
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCIK Takahashi, PW Serruys, P Chichareont et al.
-
Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin?KM Ziada; DJ Moliterno et al.
-
A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trialWJ Jang, JB Lee, YB Song et al.
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al.
-
Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trialZ Ge, JJ Zhang, SL Chen et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
